The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice

Experimental Neurology

Volumn 232, Issue 2, 2011, Pages 309-317

  Almad, Akshata ^a   Lash, A Todd ^a   Wei, Ping ^a   Lovett Racke, Amy E ^a   McTigue, Dana M ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Inflammation; Locomotor recovery; Macrophage; Myelin; Neuroprotection; PPAR alpha; Spinal cord injury; T cells; White matter sparing

Indexed keywords

FENOFIBRATE; GEMFIBROZIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; LAMINECTOMY; LOCOMOTION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD INJURY; TISSUE INJURY; TISSUE PRESERVATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FENOFIBRATE; GEMFIBROZIL; HYPOLIPIDEMIC AGENTS; MACROPHAGES; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MYELITIS; NERVE FIBERS, MYELINATED; PPAR ALPHA; RECOVERY OF FUNCTION; SPINAL CORD; SPINAL CORD INJURIES; T-LYMPHOCYTES; TREATMENT FAILURE;

EID: 80055022344     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.09.023     Document Type: Article

References (43)

1. Ankeny D.P., Guan Z., Popovich P.G. B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice. J Clin Invest 2009, 119:2990-2999.
2. Basso D.M., Fisher L.C., Anderson A.J., Jakeman L.B., McTigue D.M., Popovich P.G. Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J. Neurotrauma 2006, 23:635-659.
3. Besson V.C., Chen X.R., Plotkine M., Marchand-Verrecchia C. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury. Neurosci Lett 2005, 388:7-12.
4. Bordet R., Ouk T., Petrault O., Gele P., Gautier S., Laprais M., Deplanque D., Duriez P., Staels B., Fruchart J.C., Bastide M. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem. Soc. Trans. 2006, 34:1341-1346.
5. Brunmair B., Lest A., Staniek K., Gras F., Scharf N., Roden M., Nohl H., Waldhausl W., Furnsinn C. Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I. J Pharmacol Exp Ther 2004, 311:109-114.
6. Chen X.R., Besson V.C., Palmier B., Garcia Y., Plotkine M., Marchand-Leroux C. Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J Neurotrauma 2007, 24:1119-1131.
7. Chinetti G., Lestavel S., Bocher V., Remaley A.T., Neve B., Torra I.P., Teissier E., Minnich A., Jaye M., Duverger N., Brewer H.B., Fruchart J.C., Clavey V., Staels B. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 2001, 7:53-58.
8. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 2000, 20:558-567.
9. Dasgupta S., Roy A., Jana M., Hartley D.M., Pahan K. Gemfibrozil ameliorates relapsing-remitting experimental autoimmune encephalomyelitis independent of peroxisome proliferator-activated receptor-alpha. Mol Pharmacol 2007, 72:934-946.
10. Deb C., Lafrance-Corey R.G., Schmalstieg W.F., Sauer B.M., Wang H., German C.L., Windebank A.J., Rodriguez M., Howe C.L. CD8+ T cells cause disability and axon loss in a mouse model of multiple sclerosis. PLoS One 2010, 5:e12478.
11. Deplanque D., Gele P., Petrault O., Six I., Furman C., Bouly M., Nion S., Dupuis B., Leys D., Fruchart J.C., Cecchelli R., Staels B., Duriez P., Bordet R. Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 2003, 23:6264-6271.
12. Donnelly D.J., Popovich P.G. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp Neurol 2008, 209:378-388.
13. Fleming J.C., Norenberg M.D., Ramsay D.A., Dekaban G.A., Marcillo A.E., Saenz A.D., Pasquale-Styles M., Dietrich W.D., Weaver L.C. The cellular inflammatory response in human spinal cords after injury. Brain 2006, 129:3249-3269.
14. Genovese T., Esposito E., Mazzon E., Di Paola R., Meli R., Bramanti P., Piomelli D., Calignano A., Cuzzocrea S. Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther 2008, 326:12-23.
15. Genovese T., Esposito E., Mazzon E., Crisafulli C., Paterniti I., Di Paola R., Galuppo M., Bramanti P., Cuzzocrea S. PPAR-alpha modulate the anti-inflammatory effect of glucocorticoids in the secondary damage in experimental spinal cord trauma. Pharmacol Res 2009, 59:338-350.
16. Gocke A.R., Hussain R.Z., Yang Y., Peng H., Weiner J., Ben L.H., Drew P.D., Stuve O., Lovett-Racke A.E., Racke M.K. Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune disease. J Immunol 2009, 182:4479-4487.
17. Hulbert R.J., Hamilton M.G. Methylprednisolone for acute spinal cord injury: 5-year practice reversal. Can J Neurol Sci 2008, 35:41-45.
18. Inoue H., Jiang X.F., Katayama T., Osada S., Umesono K., Namura S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci Lett 2003, 352:203-206.
19. Ito H., Sugimoto Y., Tomioka M., Kai N., Tanaka M. Does high dose methylprednisolone sodium succinate really improve neurological status in patient with acute cervical cord injury?. Spine 2009, 34:2121-2124.
20. Jana M., Jana A., Liu X., Ghosh S., Pahan K. Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of I kappa B alpha in anti-inflammatory effect of gemfibrozil in microglia. J Immunol 2007, 179:4142-4152.
21. Johnson T.E., Zhang X., Shi S., Umbenhauer D.R. Statins and PPARalpha agonists induce myotoxicity in differentiated rat skeletal muscle cultures but do not exhibit synergy with co-treatment. Toxicol Appl Pharmacol 2005, 208:210-221.
22. Jones T.B., Basso D.M., Sodhi A., Pan J.Z., Hart R.P., MacCallum R.C., Lee S., Whitacre C.C., Popovich P.G. Pathological CNS autoimmune disease triggered by traumatic spinal cord injury: implications for autoimmune vaccine therapy. J. Neurosci. 2002, 22:2690-2700.
23. Jones T.B., Hart R.P., Popovich P.G. Molecular control of physiological and pathological T-cell recruitment after mouse spinal cord injury. J. Neurosci. 2005, 25:6576-6583.
24. Kurtz S.M., Fitzgerald J.E., Fisken R.A., Schardein J.L., Reutner T.H., Lucas J.A. Toxicological studies on gemfibrozil. Proc R Soc Med 1976, 69(Suppl 2):15-23.
25. Liu A., Xie S., Sun H., Gonzalez F.J., Wei X., Dai R. Myotoxicity of gemfibrozil in cynomolgus monkey model and its relationship to pharmacokinetic properties. Toxicol Appl Pharmacol 2009, 235:287-295.
26. Liu A., Yang J., Gonzalez F.J., Cheng G.Q., Dai R. Biphasic regulation of intracellular calcium by gemfibrozil contributes to inhibiting L6 myoblast differentiation: implications for clinical myotoxicity. Chem Res Toxicol 2011, 24:229-237.
27. Lovett-Racke A.E., Hussain R.Z., Northrop S., Choy J., Rocchini A., Matthes L., Chavis J.A., Diab A., Drew P.D., Racke M.K. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J Immunol 2004, 172:5790-5798.
28. McTigue D.M., Tripathi R.B., Wei P., Lash A.T. The PPAR gamma agonist Pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. Exp. Neurol. 2007, 205:396-406.
29. Popovich P.G., Wei P., Stokes B.T. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J. Comp Neurol. 1997, 377:443-464.
30. Popovich P.G., Guan Z., Wei P., Huitinga I., van Rooijen N., Stokes B.T. Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. Exp. Neurol. 1999, 158:351-365.
31. Profyris C., Cheema S.S., Zang D., Azari M.F., Boyle K., Petratos S. Degenerative and regenerative mechanisms governing spinal cord injury. Neurobiol. Dis. 2004, 15:415-436.
32. Pyper S.R., Viswakarma N., Yu S., Reddy J.K. PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal 2010, 8:e002.
33. Ramanan S., Kooshki M., Zhao W., Hsu F.C., Robbins M.E. PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways. Free Radic Biol Med 2008, 45:1695-1704.
34. Ramanan S., Kooshki M., Zhao W., Hsu F.C., Riddle D.R., Robbins M.E. The PPARalpha agonist fenofibrate preserves hippocampal neurogenesis and inhibits microglial activation after whole-brain irradiation. Int J Radiat Oncol Biol Phys 2009, 75:870-877.
35. Roy A., Pahan K. Gemfibrozil, stretching arms beyond lipid lowering. Immunopharmacol Immunotoxicol 2009, 31:339-351.
36. Rubenstrunk A., Hanf R., Hum D.W., Fruchart J.C., Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007, 1771:1065-1081.
37. Sanguino E., Ramon M., Roglans N., Alegret M., Sanchez R.M., Vazquez-Carrera M., Laguna J.C. Gemfibrozil increased the specific binding of rat-cortex nuclear extracts to a PPRE probe. Life Sci 2003, 73:2927-2937.
38. Smith S.A., May F.J., Monteith G.R., Roberts-Thomson S.J. Activation of the peroxisome proliferator-activated receptor-alpha enhances cell death in cultured cerebellar granule cells. J Neurosci Res 2001, 66:236-241.
39. Tripathi R., McTigue D.M. Prominent oligodendrocyte genesis along the border of spinal contusion lesions. Glia 2007, 55:698-711.
40. Wang G., Namura S. Effects of chronic systemic treatment with peroxisome proliferator-activated receptor alpha activators on neuroinflammation induced by intracerebral injection of lipopolysaccharide in adult mice. Neurosci Res 2011, 70:230-237.
41. Xu J., Storer P.D., Chavis J.A., Racke M.K., Drew P.D. Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. J Neurosci Res 2005, 81:403-411.
42. Yang Y., Gocke A.R., Lovett-Racke A., Drew P.D., Racke M.K. PPAR alpha regulation of the immune response and autoimmune encephalomyelitis. PPAR Res 2008, 2008:546753.
43. Zhao Y., Okuyama M., Hashimoto H., Tagawa Y., Jomori T., Yang B. Bezafibrate induces myotoxicity in human rhabdomyosarcoma cells via peroxisome proliferator-activated receptor alpha signaling. Toxicol In Vitro 2010, 24:154-159.